TCM
MGX icon

Tang Capital Management’s Metagenomi Therapeutics MGX Stock Holding History

Tang Capital Management’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-28,008
Closed -$66.4K – 193
2025
Q3 		$66.4K Sell
28,008
-171,992
-86% -$349K ﹤0.01% 192
2025
Q2 		$296K Buy
200,000
+65,022
+48% +$102K 0.02% 193
2025
Q1 		$184K Buy
+134,978
New +$322K 0.01% 197

Other funds holding MGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Tang Capital Management's MGX Position: Q4 2025 in Review

Tang Capital Management sold out of Metagenomi Therapeutics (MGX) in Q4 2025, closing a stake of 28,008 shares — an estimated $66.4K sold.

Tang Capital Management first reported a position in MGX in Q1 2025 and held it in 3 quarters. The position peaked at $296K in Q2 2025. 56 funds tracked by Wall St. Rank hold MGX as of Q4 2025.

  • Tang Capital Management reported no remaining Metagenomi Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Tang Capital Management sold 28,008 Metagenomi Therapeutics shares in Q4 2025, an estimated $66.4K.
  • Tang Capital Management first reported a position in Metagenomi Therapeutics in Q1 2025 and held it in 3 quarters.
  • Tang Capital Management's Metagenomi Therapeutics position peaked at $296K in Q2 2025.
  • 56 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q4 2025.

Based on Tang Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.